Japan Approves Dupixent as First Targeted Treatment for Bullous Pemphigoid, Boosting Regeneron's Key Drug
REGN sits 55% above its 52-week low of $476.487.
Summary
Sanofi and Regeneron's Dupixent has received marketing and manufacturing authorization in Japan for the treatment of adults with moderate-to-severe bullous pemphigoid (BP), becoming the first targeted medicine for this chronic skin condition. This approval, based on pivotal study results demonstrating significantly higher sustained disease remission with Dupixent, marks the seventh approved indication for the drug in Japan. This positive regulatory development for Dupixent, a key revenue driver highlighted in Regeneron's recent 10-K, reinforces its growth trajectory and expands its addressable market. The entry into a new, underserved indication is a material positive for Regeneron, potentially contributing to future revenue growth. Traders will monitor the commercial launch and sales uptake in Japan, as well as potential for similar approvals in other major markets.
At the time of this announcement, REGN was trading at $736.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.9B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.